Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
HCA Healthcare Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Assets
- Analysis of Reportable Segments
- Common Stock Valuation Ratios
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Net Profit Margin since 2011
- Return on Assets (ROA) since 2011
- Total Asset Turnover since 2011
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to HCA Healthcare Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
HCA Healthcare Inc., profitability ratios (quarterly data)
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
- Gross Profit Margin
- The gross profit margin remained relatively stable over the reported periods, consistently around 83.2% to 84.0%. Small incremental increases are noted, indicating a steady ability to maintain profitability on core operations before operating expenses.
- Operating Profit Margin
- The operating profit margin showed moderate fluctuations, initially increasing from approximately 13.9% in early 2017 to a peak around 15.3% in 2021, then rising significantly to 18.7% in early 2022. This upward trend suggests improved operational efficiency or cost control over time, especially notable in the latter periods.
- Net Profit Margin
- Net profit margin demonstrated marked improvement across the quarters, beginning near 5.1% in early 2017 and climbing steadily to over 11% by early 2022. The ascent reflects enhanced bottom-line profitability, potentially driven by effective cost management, revenue growth, or other financial strategies.
- Return on Equity (ROE)
- ROE values are reported for limited periods, showing exceptionally high figures of 656.29% and 1860.73% around the 2020 to 2021 timeframe. These unusually large ROE figures may indicate extraordinary events, accounting adjustments, or anomalies affecting equity or net income, warranting further investigation for clarity.
- Return on Assets (ROA)
- Return on assets displayed a clear upward trend over the periods, rising from approximately 6.1% in early 2017 to around 13.7% by early 2022. This improvement points to increasingly efficient use of asset base to generate profit, supporting the overall growth in profitability metrics.
Return on Sales
Return on Investment
Gross Profit Margin
HCA Healthcare Inc., gross profit margin calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| Gross profit margin1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| CVS Health Corp. | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q1 2022 Calculation
Gross profit margin = 100
× (Gross profitQ1 2022
+ Gross profitQ4 2021
+ Gross profitQ3 2021
+ Gross profitQ2 2021)
÷ (RevenuesQ1 2022
+ RevenuesQ4 2021
+ RevenuesQ3 2021
+ RevenuesQ2 2021)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Gross Profit Trend
- The gross profit figures exhibit a generally increasing trend over the analyzed period, moving from $8,826 million in the first quarter of 2017 to approximately $12,624 million by the first quarter of 2022. There is a noticeable dip during mid-2020, corresponding with $9,320 million in the second quarter, likely reflecting external challenges during that period. Post this decline, the gross profit shows a recovery and subsequent growth towards the end of 2021 and early 2022.
- Revenues Trend
- Revenues follow a pattern similar to gross profit, increasing from $10,623 million in Q1 2017 up to $14,945 million by Q1 2022. The revenue peak is observed in Q4 2021 at $15,276 million. A decline is apparent in the first half of 2020, with revenues falling to $11,068 million in Q2 2020, consistent with the gross profit contraction during the same period. Recovery is evident subsequently with growth resuming through 2021.
- Gross Profit Margin Stability
- The gross profit margin percentage remains remarkably stable and consistent throughout, ranging narrowly between roughly 83.2% and 84.0%. This suggests the company maintained its profitability efficiency despite fluctuations in both gross profit and total revenues. The margin exhibits a slight gradual upward trend over time, indicating improved cost control or pricing power.
- Overall Insights
- The data reveals overall growth in both gross profit and revenues over the five-year timeframe, demonstrating an expansion in operational scale or market reach. The notable decline in mid-2020 across key financial metrics likely corresponds to broader economic disruptions during that period, followed by a steady recovery. The gross profit margin's stability highlights effective management of cost structures, even amid challenging conditions.
Operating Profit Margin
HCA Healthcare Inc., operating profit margin calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Operating income | ||||||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| Operating profit margin1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| CVS Health Corp. | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q1 2022 Calculation
Operating profit margin = 100
× (Operating incomeQ1 2022
+ Operating incomeQ4 2021
+ Operating incomeQ3 2021
+ Operating incomeQ2 2021)
÷ (RevenuesQ1 2022
+ RevenuesQ4 2021
+ RevenuesQ3 2021
+ RevenuesQ2 2021)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Revenues
- Revenues exhibited a general upward trend from the first quarter of 2017 through early 2020, increasing from approximately $10.6 billion in March 2017 to a peak of about $13.5 billion in December 2019. However, starting in the first half of 2020, revenues notably declined, reaching around $11.1 billion in June 2020, likely reflecting external disruptions during that period. Subsequently, revenues recovered and resumed growth, reaching levels above $15 billion by the end of 2021, indicating a strong rebound and growth momentum.
- Operating Income
- Operating income followed a somewhat volatile trajectory across the analyzed period. Initially, it fluctuated between $1.2 billion and $1.9 billion from 2017 to 2019, without a clear directional trend. In early 2020, operating income declined sharply to $1.33 billion in the third quarter but rebounded strongly in the final quarter of 2020, climbing to $2.45 billion, the highest point observed in the data. This upward momentum continued through most of 2021, peaking at $3.52 billion in the third quarter before falling back to approximately $2.2 billion in the first quarter of 2022. These fluctuations suggest operational challenges and strong recovery phases, possibly linked to external market conditions and internal efficiency improvements.
- Operating Profit Margin
- The operating profit margin remained relatively stable in the early period measured, fluctuating modestly around 14-15% between 2017 and 2019. In 2020, there was a slight decrease, with margins dropping to near 13.3% in the second quarter, possibly due to pandemic-related cost pressures. Margins strengthened significantly in 2021, with a notable increase to over 18% and peaking at 19.23% in the third quarter, reflecting improved operational efficiency or favorable cost management relative to revenues. There was a minor decline at the start of 2022, but the margin remained elevated compared to pre-pandemic levels.
- Overall Trends and Insights
- The data indicates a stable revenue growth trend interrupted by a significant decline in early 2020, followed by a strong recovery and growth resumption by the end of 2021. Operating income reflects higher volatility, closely aligned with operating profit margin trends, indicating fluctuating profitability potentially tied to external factors such as market conditions and internal cost control efforts. The enhanced profit margins in 2021 signify improved profitability and suggest that operational efficiencies or pricing strategies were successfully executed during the recovery period. However, the early 2022 decline in operating income and profitability margin may warrant closer monitoring for sustainability of these improvements.
Net Profit Margin
HCA Healthcare Inc., net profit margin calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Net income attributable to HCA Healthcare, Inc. | ||||||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| Net profit margin1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| CVS Health Corp. | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q1 2022 Calculation
Net profit margin = 100
× (Net income attributable to HCA Healthcare, Inc.Q1 2022
+ Net income attributable to HCA Healthcare, Inc.Q4 2021
+ Net income attributable to HCA Healthcare, Inc.Q3 2021
+ Net income attributable to HCA Healthcare, Inc.Q2 2021)
÷ (RevenuesQ1 2022
+ RevenuesQ4 2021
+ RevenuesQ3 2021
+ RevenuesQ2 2021)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Net Income Attributable to HCA Healthcare, Inc.
- The net income figures demonstrate notable fluctuations over the analyzed periods. Initial quarterly results in 2017 show a moderate range between 426 million and 659 million US dollars. Substantial growth is observed in 2018, with net income peaking above 1 billion US dollars in multiple quarters, indicating improved profitability. Despite a dip in early 2020, coinciding with the global pandemic context, the net income rebounded sharply in late 2020 and especially in 2021, reaching a peak of 2,269 million US dollars in the fourth quarter of 2021. The first quarter of 2022 reflects a decrease from prior highs but remains elevated relative to earlier years.
- Revenues
- Revenues show a consistent upward trend from 2017 through 2021, rising from approximately 10.6 billion US dollars in the first quarter of 2017 to over 15 billion US dollars in the latter part of 2021. A transient decline appears in mid-2020, likely linked to external economic disruptions, before recovering to new highs. The first quarter of 2022 indicates a slight reduction compared to the previous quarter but maintains higher values compared to the earlier years in the series.
- Net Profit Margin
- Profit margin percentages, recorded from the fourth quarter of 2017 onwards, reveal a progressive improvement in operational efficiency and profitability. Starting at just over 5% in late 2017, margins steadily increase, peaking in late 2021 at nearly 12%. Although a slight decline is evident in early 2022, the margins remain significantly higher compared to the earlier observed values, suggesting sustained profitability growth over the period.
- Overall Insights
- The financial indicators collectively illustrate a strong growth trajectory in both revenues and net income over the reported quarters, signifying effective business scaling and margin enhancement. The temporary setbacks during 2020 correspond with global economic challenges, yet the rapid recovery and subsequent record profitability highlight resilience and operational strength. The consistent improvement in net profit margin further underscores enhanced cost management and revenue quality during the period analyzed.
Return on Equity (ROE)
HCA Healthcare Inc., ROE calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Net income attributable to HCA Healthcare, Inc. | ||||||||||||||||||||||||||||
| Stockholders’ equity (deficit) attributable to HCA Healthcare, Inc. | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| ROE1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| CVS Health Corp. | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q1 2022 Calculation
ROE = 100
× (Net income attributable to HCA Healthcare, Inc.Q1 2022
+ Net income attributable to HCA Healthcare, Inc.Q4 2021
+ Net income attributable to HCA Healthcare, Inc.Q3 2021
+ Net income attributable to HCA Healthcare, Inc.Q2 2021)
÷ Stockholders’ equity (deficit) attributable to HCA Healthcare, Inc.
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The net income attributable to the company exhibits notable fluctuations over the periods analyzed. Initially, from the first quarter of 2017 until the end of 2017, net income showed variability, with a peak of 1144 million US$ observed in the first quarter of 2018. A decline followed during mid-2018 through 2019, reaching a lower point of 581 million US$ in the first quarter of 2020. Subsequently, there was a strong upward trend from mid-2020 onwards, culminating in a peak of 2269 million US$ at the end of 2021, before decreasing to 1273 million US$ in the first quarter of 2022. This indicates periods of volatility with a significant recovery and growth phase after early 2020.
Stockholders’ equity attributable to the company started with negative values consistently through the years, indicating a deficit position. The deficit reduced steadily from -7017 million US$ in March 2017 to a substantially smaller negative balance of 572 million US$ by the end of 2020, even turning positive briefly at that point. However, after this improvement, equity reverted to negative territory again through 2021 and into 2022, reaching -2033 million US$ by March 2022. This pattern suggests some recovery efforts but continued underlying challenges affecting equity stability.
The Return on Equity (ROE) data is mostly unavailable except for the last two reported quarters, which show extremely high values of 656.29% and 1860.73%. These elevated ROE figures likely result from the very low or negative equity base, which can distort this ratio, making it less reliable for assessing profitability during these periods.
- Net Income Trend
- Fluctuated with initial highs and subsequent declines, followed by a strong recovery peaking towards the end of 2021.
- Stockholders’ Equity Trend
- Consistently negative initially, moving towards a slight positive in late 2020, then diminishing again into negative values through early 2022.
- Return on Equity (ROE)
- Extremely high in the latest periods, but this is likely influenced by the negative or minimal equity values, reducing the interpretive reliability of ROE.
Overall, the data reveals substantial volatility in net income alongside persistent equity challenges. The recovery in net income after early 2020 highlights an improvement in profitability, yet the ongoing negative equity indicates potential structural financial issues that may require further management attention.
Return on Assets (ROA)
HCA Healthcare Inc., ROA calculation (quarterly data)
| Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
| Net income attributable to HCA Healthcare, Inc. | ||||||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||||
| ROA1 | ||||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||||
| Abbott Laboratories | ||||||||||||||||||||||||||||
| CVS Health Corp. | ||||||||||||||||||||||||||||
| Elevance Health Inc. | ||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | ||||||||||||||||||||||||||||
| Medtronic PLC | ||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | ||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31).
1 Q1 2022 Calculation
ROA = 100
× (Net income attributable to HCA Healthcare, Inc.Q1 2022
+ Net income attributable to HCA Healthcare, Inc.Q4 2021
+ Net income attributable to HCA Healthcare, Inc.Q3 2021
+ Net income attributable to HCA Healthcare, Inc.Q2 2021)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reflects several notable trends and fluctuations over the analyzed periods. Net income attributable to the company demonstrates variability with a general upward trend interrupted by short-term declines. After an initial range between approximately 426 million and 1144 million US dollars during 2017 and 2018, net income dropped significantly in early 2020 before rebounding strongly, reaching a peak in late 2020 and early 2021. However, a subsequent downward trend is observed through to the first quarter of 2022.
Total assets show consistent growth across the entire timeline, increasing steadily from approximately 33.8 billion US dollars in early 2017 to over 52.2 billion US dollars by the first quarter of 2022. This suggests ongoing investments or asset acquisitions contributing to the expanding asset base.
Return on assets (ROA) data, available from the first quarter of 2018 onwards, indicates an overall improving profitability relative to asset base. Starting around 6.06%, it generally increases to surpass 13% by late 2021, evidencing improved efficiency or profitability in asset utilization. The ROA trend correlates positively with net income fluctuations, with both metrics peaking towards the end of 2021.
- Net Income Trends
- Initial fluctuation in net income is followed by a sharp increase in 2018, a notable decline at the onset of 2020, likely reflecting external challenges, then a strong recovery through 2020 and early 2021. The latest data indicates a declining trend in early 2022.
- Asset Growth
- Assets steadily increased throughout the period, implying continued growth and expansion activities, with the asset base growing by over 50% from 2017 to 2022.
- Return on Assets (ROA)
- ROA improved significantly over the period, showing enhanced profitability per dollar of assets. The rising ROA aligns with the periods of increased net income, highlighting a correlation between profitability and asset utilization effectiveness.
In summary, the entity has experienced growth in asset base and overall profitability improvements over the five-year period, with some interruptions likely due to external factors. The increases in ROA and net income during the post-2020 period indicate recovery and successful adaptation, although caution is warranted given the recent decline in profitability at the beginning of 2022.